Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 4/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17880354 | 0.76 | ALDH1A1 (0.31) | CYP1A2HPGDHSD17B10ALDH1A1CYP3A4 | |
| SCHEMBL25639338 | 0.76 | HSD17B10 (0.52) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL25639351 | 0.76 | HSD17B10 (0.52) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL17880358 | 0.76 | ALDH1A1 (0.37) | CYP1A2HPGDHSD17B10ALDH1A1CYP3A4 | |
| SCHEMBL17880355 | 0.73 | ALDH1A1 (0.41) | CYP1A2HPGDHSD17B10ALDH1A1CYP3A4 | |
| SCHEMBL17880366 | 0.72 | ALDH1A1 (0.33) | CYP1A2HPGDHSD17B10ALDH1A1CYP3A4 | |
| SCHEMBL17880368 | 0.72 | ALOX5 (0.31) | — | |
| SCHEMBL17790844 | 0.68 | CYP1A2 (0.34) | CYP1A2HPGDHSD17B10ALDH1A1THRB | |
| SCHEMBL13228961 | 0.68 | CYP1A2 (0.37) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL13228960 | 0.68 | CYP1A2 (0.37) | CYP1A2ERBB2FYNMAOAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793063-B2 | Condensed-cyclic compound and organic light emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-10-17 | — | — | US | disclosed |
| US-11793063-B2 | Condensed-cyclic compound and organic light emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-10-17 | — | — | US | disclosed |
| US-20160190450-A1 | CONDENSED-CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-06-30 | — | — | US | disclosed |
| US-20160190450-A1 | CONDENSED-CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11793063-B2 | Condensed-cyclic compound and organic light emitting device including the same | CRY1, CRY2, CCNE2 | CYP1A2 1346/4885ERBB2 4545/4885FYN 4641/4885 |
| US-20160190450-A1 | CONDENSED-CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | CRY1, CRY2, CCNE2 | CYP1A2 1346/4885ERBB2 4545/4885FYN 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.